|ZEN Graphene Solutions Ltd.|
Medicine Medical SuppliesAntiviral ink
GrapheneC Graphene CAS Number : 7782-42-5
SilverAg Nanoparticle /Nanopowder CAS Number : 7440-22-4
ZEN Graphene Solutions Ltd has announced an international collaboration with UK-based Graphene Composites Ltd to fight COVID-19 by developing a potential virucidal graphene-based composite ink that can be applied to fabrics including N95 face masks and other personal protective equipment (PPE) for significantly increased protection. Once the development, testing, and confirmation of the graphene ink’s virucidal ability have been completed, the ink will then be incorporated into fabrics used for PPE.
The development of this potential COVID-19 virucidal graphene ink is coming at a crucial time to provide effective PPE supplies for the safety of frontline workers and hospital staff. The current N95 masks trap the virus but don’t kill it. Its testing will demonstrate if the graphene ink is an effective virucide which would kill the virus as this could make a big difference to people’s safety.
Combining the deep nanomaterials expertise of GC and ZEN with a truly collaborative approach has enabled us to do a year’s worth of R&D in a matter of weeks. Quickly developing and deploying the virucidal/germicidal ink would make a significant difference in slowing the rate of infection – thus saving many lives.
Under the collaboration, ZEN has synthesized a silver nanoparticles functionalized graphene oxide ink at their lab in Guelph, Ontario that has been documented by previous researchers to kill earlier versions of coronavirus. Once testing is completed, the ZEN/GC graphene ink would then be incorporated into a fabric to be included into masks and filters designed by GC.
Efficacy testing of the silver-graphene oxide-based ink to kill the COVID 19 virus (SARS-CoV-2) will be conducted at Western University’s ImPaKT Facility Biosafety Level 3 lab in Ontario. In addition, the graphene ink will be tested to kill influenza A and B viruses at Biosafety Level 2 labs in the UK and US.